Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

ClinicalTrials.gov ID: NCT00440648

Public ClinicalTrials.gov record NCT00440648. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Cross-Over Design Study of Sevelamer Hydrochloride (Renagel®) and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a double-blind, randomized, cross-over study conducted at centers within the United States. The study consists of five periods: an up to two-week Screening Period, a 5-week Run-In Period, two eight-week study treatment periods and a two-week Washout Period. Patients are assigned randomly (1:1) to one of two treatment sequences: sevelamer carbonate for eight weeks followed by sevelamer hydrochloride for eight weeks or sevelamer hydrochloride for eight weeks followed by sevelamer carbonate for eight weeks

Study identification

NCT ID: NCT00440648
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genzyme, a Sanofi Company; Industry
Enrollment: 80 participants

Conditions and interventions

Conditions

Chronic Kidney Disease

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 2005 (Type not available)
Primary completion: Mar 2006 (Actual)
Completion: Jul 2006 (Actual)
Last update posted: Mar 19, 2014

2005 – 2006

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
Not listed	Mobile	Alabama	36608	—
Not listed	Riverside	California	92501	—
Not listed	Greenwood Village	Colorado	80111	—
Not listed	Berwyn	Illinois	60402	—
Not listed	Crestwood	Illinois	60445	—
Not listed	Indianapolis	Indiana	46202	—
Not listed	Valparaiso	Indiana	46383	—
Not listed	Columbus	Missouri	39705	—
Not listed	St Louis	Missouri	63103	—
Not listed	St Louis	Missouri	63110	—
Not listed	Winston-Salem	North Carolina	27157	—
Not listed	Easton	Pennsylvania	19045	—
Not listed	Wynnewood	Pennsylvania	19096	—
Not listed	Nashville	Tennessee	37205	—
Not listed	Norfolk	Virginia	23507	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00440648, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 19, 2014 · Synced Nov 4, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00440648 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →